Global Trachoma Market, By Treatment (Medication, Surgery, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the trachoma market is anticipated to grow rapidly during the forecast period. Trachoma is an infectious eye illness caused by the bacteria Chlamydia trachomatis, and it is the largest cause of blindness and one of 20 neglected tropical diseases that impact one billion of the world's poorest people, according to the World Health Organization (WHO). Furthermore, according to the World Health Organization (2018), an estimated 89.1 million people have been treated with medicines to eliminate trachoma, boosting the market's revenue growth.
Data Bridge Market Research analyses that the trachoma market was valued at USD 514.66 million in 2021 and is expected to reach USD 789.84 million by 2029, registering a CAGR of 5.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Trachoma is a bacterial infection that affects the surface of the eyes and is very contagious. Scar tissue or ulcers can build over time, leading to blindness. It spreads when bacteria in an infected person's ocular secretions move to others, either through person-to-person contact or through eye-seeking flies, particularly the Musca sorbens fly. It is especially common in endemic populations where there is a shortage of sanitation and clean water.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Medication, Surgery, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Abbott (US), AbbVie Inc. (US), Arbor Pharmaceuticals, Inc (US), Apotex Inc. (Canada), Fresenius Kabi AG (Germany)
|
|
Market Opportunities
|
|
Trachoma Market Dynamics
Drivers
- Increasing prevalence of trachoma
The rising prevalence of trachoma is a primary driver of the trachoma market's growth. As per the World Health Organization (WHO), 157.7 million people are suffering from trachoma across the globe and approximately 2 million people have become blind.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of trachoma market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the trachoma market. Additionally, high disposable income and favorable government initiatives will result in the expansion of trachoma market. Along with this, rising incidences of eye infection and poor sanitation will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the trachoma market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the trachoma market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of trachoma will obstruct the growth rate of market. The low diagnosis rate and lack of healthcare infrastructure in developing economies will challenge the trachoma market. Additionally, a lack of awareness about the treatment and side effects linked with the medication will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This trachoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the trachoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Trachoma causes blindness or vision impairment in around 1.9 million people worldwide, and it is still a public health issue in 44 countries. Trachoma is present in around 21 million persons around the world. The bulk of the victims are children around 3-6 years old. The disease is mostly found near the equator in dry, arid environments, with Sub-Saharan Africa having the most instances.
Trachoma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Trachoma Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of trachoma in recent months.
Global Trachoma Market Scope
The trachoma market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Surgery
- Others
On the basis of treatment, the global trachoma market is segmented into medication and surgery. Medication can be further segmented into tetracycline, macrolides, ophthalmic anti-infective, sulfonamides, and others.
Route of Administration
- Oral
- Topical
- Others
The route of administration segment for the trachoma market is segmented into oral, topical and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the trachoma market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the trachoma market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Trachoma Market Regional Analysis/Insights
The Trachoma market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Trachoma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Middle East and Africa dominates the trachoma market because of the growing prevalence of trachoma in this region. Additionally, growing focus of major key players will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Trachoma Market Share Analysis
The Trachoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to trachoma market.
Some of the major players operating in the trachoma market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Bausch Health Companies Inc. (Canada)
- Abbott (US)
- Arbor Pharmaceuticals, Inc (US)
- Apotex Inc. (Canada)
- Fresenius Kabi AG (Germany)
SKU-